Inflammatory Ly-6C<sup>hi</sup> monocytes play an important role in the development of severe transplant arteriosclerosis in hyperlipidemic recipients

Alexandru Schiopu<sup>a</sup>,* Satish N. Nadig<sup>a</sup>, Ovidiu S. Cotoi<sup>b,++</sup>, Joanna Hester<sup>a</sup>, Nico van Rooijen<sup>c</sup>, Kathryn J. Wood<sup>d</sup>

<sup>a</sup>Transplantation Research Immunology Group, University of Oxford, Nuffield Department of Surgical Sciences, John Radcliffe Hospital, Oxford, UK
<sup>b</sup>Department of Cellular and Molecular Biology, University of Medicine and Pharmacy of Targu Mures, Targu Mures, Romania
<sup>c</sup>Department of Molecular Cell Biology, VUMC, Amsterdam, The Netherlands

**A B S T R A C T**

Objective: Transplant arteriosclerosis (TA) restricts long-term survival of heart transplant recipients. Although the role of monocyte/macrophages is well established in native atherosclerosis, it has been studied to a much lesser extent in TA. Plasma cholesterol is the most important non-immunologic risk factor for development of TA but the underlying mechanisms are largely unknown. We hypothesized that monocyte/macrophages might play an important role in the pathogenesis of TA under hyperlipidemic conditions.

Methods: We studied TA in fully mismatched arterial allografts transplanted into hyperlipidemic ApoE<sup>−/−</sup> recipients compared to wild-type controls. The recruitment of distinct monocyte populations into the grafts was tracked by in vivo labelling with fluorescent microspheres. We used antibody-mediated depletion protocols to dissect the relative contribution of T lymphocytes and monocytes to disease development.

Results: In the hyperlipidemic environment the progression of TA was highly exacerbated and the inflammatory CD11b<sup>+</sup>CD115<sup>+</sup>Ly-6C<sup>hi</sup> monocytes were preferentially recruited into the neointima. The number of macrophage-derived foam cells present in the grafts strongly correlated with plasma cholesterol and disease severity. Depletion of Ly-6C<sup>hi</sup> monocytes and neutrophils significantly inhibited macrophage accumulation and disease progression. The accelerated monocyte recruitment occurs through a T cell-independent mechanism, as T cell depletion did not influence macrophage accumulation into the grafts.

Conclusions: Our study identifies for the first time the involvement of inflammatory Ly-6C<sup>hi</sup> monocytes into the pathogenesis of TA, particularly in conditions of hyperlipidemia. Targeted therapies modulating the recruitment and activation of these cells could potentially delay coronary allograft vasculopathy and improve long-term survival of heart transplant recipients.

© 2012 Elsevier Ireland Ltd. Open access under CC BY license.

1. Introduction

The development of cardiac allograft vasculopathy or transplant arteriosclerosis (TA) restricts long-term survival of heart transplant recipients [1,2]. TA is a fibroproliferative disease of the arterial vasculature, characterised by neointimal hyperplasia due to smooth muscle cell (SMC) proliferation and accumulation of extracellular matrix proteins. Unlike the focal atheromas characteristic of native atherosclerosis, TA lesions are concentric and diffusely spread throughout the coronary vasculature [3]. The most important trigger of TA development is the alloimmune-mediated injury of the graft vasculature, leading to endothelial activation and immune cell recruitment. Both innate and the adaptive immune mechanisms are involved in the pathogenesis of the disease [4].

Coronary allograft vasculopathy is the second most common cause of death in long-term survivors of heart transplantation, after malignancy [5]. Significant allograft vasculopathy develops in over
50% of heart allografts by 10 years after transplantation [5,6] and rapid initial disease progression is indicative of an increased risk for early myocardial infarction and mortality [7]. Unfortunately, due to the diffuse character of the disease, coronary revascularization procedures are inefficient and do not improve long-term survival [3].

Post-transplant hyperlipidemia accelerates the development of TA in cardiac allografts [8–10] and plasma cholesterol was found to be a strong independent predictor of major adverse cardiac events in heart transplant recipients [11]. A massive accumulation of lipid-rich lesions was observed in the coronary arteries of transplanted human hearts [12]. In animal studies hypercholesterolemia was associated with accelerated TA development [13–15]. However, the underlying pathogenic mechanisms linking hyperlipidemia with enhanced development of TA and the role of the different cellular populations in this process are largely unknown.

By using fully allogeneic arterial grafts transplanted into normolipemic wild-type or hyperlipidemic ApoE−/− mice we show that the hyperlipidemic recipients develop severe TA, characterized by intense foam cell infiltration into the neointima. Hyperlipidemia specifically enhances the recruitment of the inflammatory CD11b+CD115 Ly-6Chi monocyte subset into the grafts and the macrophage accumulation strongly correlates with plasma cholesterol and the size of the lesions. Antibody-mediated depletion of Ly-6Chi monocytes and neutrophils decreases intimal expansion and macrophage infiltration, suggesting an active role of these cells in the pathogenesis of the disease.

2. Materials and methods

Please consult the “Supplementary methods” section for a detailed description.

2.1. Animals

Sex- and age-matched male and female CBA.Ca (H2b), C57BL/6 (H2b), C57BL/6 ApoE−/− (H2b) and C57BL/6 Rag−/− (H2b) mice were used as vessel donors and/or transplant recipients as specified in the text.

2.2. Aorta transplantation and tissue analysis

Aortic segments harvested from CBA.Ca mice were transplanted into fully allogeneic C57BL/6 wild-type (wt) or ApoE−/− recipients by an end-to-end infrarenal interposition technique as previously described [16]. The mice were fed either a regular mouse diet or a high fat diet (HFD) containing 21.4% fat and 0.15% supplementary cholesterol (Dietex International, Witham, UK). The HFD was initiated 2 weeks before transplantation and continued for the entire duration of the experiment. The grafts were harvested 21 days after transplantation unless otherwise specified. For morphometric analysis, 5 sections from each graft were collected at 200 μm intervals and stained with Miller’s Elastin/van Gieson. The percentage of the lumen occupied by the neointima, termed intimal expansion, was calculated as % Intimal expansion = (A1/A2) × 100, where A1 is the area of the neointima and A2 is the luminal area.

2.3. Immunostaining

Immunohistochemistry and immunofluorescence were performed on 10 μm frozen sections. Oxidized LDL (oxLDL) was detected as previously described [17] using a recombinant human IgG1 antibody binding to a specific ApoB-100 epitope (Biolvent AB, Lund, Sweden). T cells were stained with biotinylated rat anti-mouse CD4 and CD8 antibodies (eBioscience, Hatfield, UK) and macrophages with biotinylated rat anti-mouse CD68 (AbD Serotec, Oxford, UK) or CD11b (eBioscience, Hatfield, UK) antibodies as specified in the text. For immunofluorescence, macrophages were stained using biotinylated anti-mouse CD11b followed by a detection step with streptavidin-Alexa Fluor 594 (Invitrogen, USA). Smooth muscle cells were stained with Cy3-conjugated mouse anti-α actin (Sigma, USA).

2.4. In vivo monocyte labelling

The CD11b+CD115 Ly-6Chi and the CD11b+CD115 Ly-6Chi monocyte populations were differentially labelled in vivo using a protocol based on monocyte uptake of green fluorescent latex Fluoresbrite YG microspheres (Polysciences Inc., USA) [18]. The monocytes were labelled 10 days after transplantation to allow for neointima development and the mice were sacrificed 4 days later.

2.5. Flow-cytometric analysis

Cellular preparations were stained using the following fluorochrome-conjugated antibodies: CD11b-PE, CD115-APC, CD3-PECy7, CD4-PB, CD8-PercP and GR1-biotin followed by streptavidin-APC/Cy7 (eBioscience). The signal from the green fluorescent microspheres was detected in the FITC channel.

2.6. Statistics

All statistical analyses were performed using the non-parametric two-tailed Mann–Whitney test. Data are presented as mean ± SEM (standard error of the mean) or as box plots. The difference between the groups was considered to be statistically significant at P ≤ 0.05.

3. Experimental results

3.1. Hyperlipidemia accelerates TA

All of the allogeneic aortic grafts transplanted into immunocompetent mice developed TA, characterized by expansion of the neointima towards the vascular lumen (Fig. 1A–C). Disease progression was significantly accelerated in the ApoE−/− recipients, both in mice fed regular mouse diet and those fed HFD, compared to the wt controls. Average TA increased by 100% in the ApoE−/− group (33.9 ± 2.4%) and by 250% in the ApoE−/− HFD group (59.6 ± 4.9%) compared to the wt control (16.6 ± 4.7%) (Fig. 1E). TA did not develop in CBA.Ca aortas transplanted into immunodeficient C57BL/6 Rag−/− mice (not shown) or in ApoE−/− aortas transplanted into syngeneic ApoE−/− HFD recipients (Fig. 1D). These findings suggest that a competent anti-allogeneic adaptive immune response is required for the initiation and progression of TA and that the surgery-associated vascular trauma and hyperlipidemia alone do not initiate vascular lesions in the graft. The extent of intimal expansion strongly correlated with plasma levels of total cholesterol and LDL cholesterol (Fig. 1F and Supplemental table 1). We have also found a weaker correlation between intimal expansion and plasma triglyceride levels (Supplemental table 1). The total number of blood monocytes at the time of harvest was significantly elevated in the ApoE−/− mice kept on HFD for a total of 5 weeks compared with the wt mice and the ApoE−/− mice on a regular diet. The circulating neutrophil numbers did not differ significantly among the three groups (Supplemental table 2).
3.2. Hyperlipidemia triggers important histological changes of the neointima in the ApoE\textsuperscript{−/−} recipients

The ORO staining revealed a heavy lipid infiltration in aortic grafts harvested from the ApoE\textsuperscript{−/−}/C0/C0 recipients (Supplemental Fig. 1B). OxLDL was absent in the neointima but was consistently found in the innermost layer of the media in the ApoE\textsuperscript{−/−}/C0/C0 HFD group, indicating the presence of a local pro-oxidative environment (Supplemental Fig. 1D). No lipid infiltration or oxLDL staining were detected in grafts harvested from wt recipients (Supplemental Figs. 1A and C).

In the ApoE\textsuperscript{−/−}/HFD mice the CD11b\textsuperscript{+} foam cells were the dominant infiltrating cell type in the grafts and their location coincided with the lipid deposits (Supplemental Fig. 1F). In the wt group CD11b\textsuperscript{+} cells lacked the foam cell appearance and were present throughout the lesion (Supplemental Fig. 1E). In the wt recipients neointima was almost exclusively formed by a thin layer of vascular SMC (Supplemental Fig. 1G). In contrast, in the ApoE\textsuperscript{−/−}/HFD mice the SMC formed a thick distinct layer located on the luminal side of the graft, which appears to be complementary to the foam cell layer (Supplemental Fig. 1F and H).

3.3. Macrophage accumulation into the grafts correlates with TA severity

The macrophage content of the lesions, measured as percentage CD68\textsuperscript{+} stained area reported to total lesion area, was doubled in the ApoE\textsuperscript{−/−} mice on normal mouse diet (11.8 ± 2.5%) and more than tripled in the ApoE\textsuperscript{−/−} mice on HFD (22.0 ± 3.8%) compared to the wt controls (6.3 ± 2.8%) (Fig. 2A and B). We found a highly significant direct correlation between total plasma cholesterol and the presence of macrophages in the neointima ($R^2 = 0.847$, $P < 0.001$) (Fig. 2C). Furthermore, the intensity of macrophage infiltration strongly correlated with the extent of TA ($R^2 = 0.751$, $P < 0.001$) (Fig. 2D).

3.4. T cell recruitment into the allograft is not dependent on hyperlipidemia and does not correlate with macrophage content

Both CD4\textsuperscript{+} and CD8\textsuperscript{+} T cells infiltrate the arterial grafts in all recipients (Supplemental Fig. 2). The Th1 subset of CD4\textsuperscript{+} T cells and their secreted cytokine IFN\textgamma are major contributors to the development of vascular lesions in transplants [4]. In order to determine whether the accelerated lesion development in the ApoE\textsuperscript{−/−} mice is mediated through increased CD4\textsuperscript{+} T cell recruitment, we counted the numbers of CD4\textsuperscript{+} T cells infiltrating the neointima. The absolute number of CD4\textsuperscript{+} T cells was significantly increased in grafts harvested from the ApoE\textsuperscript{−/−} HFD mice (Fig. 3A). However, there was no difference between the groups when we reported the number of CD4\textsuperscript{+} T cells relative to the size of the lesion, indicating a similar recruitment rate of these cells into the grafts in the normolipidemic and the hyperlipidemic environments (Fig. 3B).

In order to test whether the increased monocyte recruitment is T cell dependent, we treated a group of ApoE\textsuperscript{−/−} HFD recipients with
3.5. Hyperlipidemia accelerates the recruitment of inflammatory Ly-6C\textsuperscript{hi} monocytes into the graft

Monocytes can be functionally divided in 2 main subpopulations; inflammatory CD11b\textsuperscript{hi}CD115\textsuperscript{hi}Ly-6C\textsuperscript{hi} (GR1\textsuperscript{hi}) and resident CD11b\textsuperscript{lo}CD115\textsuperscript{lo}Ly-6C\textsuperscript{lo} (GR1\textsuperscript{lo}) [19]. By using an in vivo protocol based on monocyte uptake of fluorescent latex microspheres [18] we differentially labelled the two populations in 2 groups of wt and 2 groups of ApoE\textsuperscript{−/−} HFD recipients of CBA.Ca aortic grafts (Supplemental Fig. 4). The monocytes were labelled 10 days after transplantation and the arterial grafts were harvested 4 days later as the 2 monocyte populations remain distinctly labelled within this time frame [18].

The fluorescent microspheres were present in the arterial grafts in all 4 groups of mice at the time of harvest (not shown). Whereas the Ly-6C\textsuperscript{lo} monocytes were preferentially located under the endothelium, the inflammatory Ly-6C\textsuperscript{hi} monocytes penetrated deep into the neointima through to the internal elastic lamina (Fig. 4A and B). Fluorescent anti-CD11b and anti-GR1 counter-staining of the grafts revealed that the microspheres are mainly located inside the infiltrating CD11b\textsuperscript{+} and GR1\textsuperscript{+} cells and that both microsphere\textsuperscript{+} and microsphere\textsuperscript{−} CD11b\textsuperscript{+} and GR1\textsuperscript{+} cells are present into the neointima (Fig. 4C–F). We quantified the microsphere content of the neointima as green fluorescent positive area per total lesion area. Significantly more fluorescent microspheres infiltrated the grafts in recipients where the Ly-6C\textsuperscript{hi} monocytes were labelled compared to their Ly-6C\textsuperscript{lo} counterparts both in wt (mean ± SEM 0.55 ± 0.29% vs. 0.09 ± 0.03%, P < 0.05) and ApoE\textsuperscript{−/−} HFD mice (3.23 ± 0.88% vs. 0.29 ± 0.04%, P < 0.01) (Fig. 4G). The hyperlipidemic environment led to accelerated recruitment of Ly-6C\textsuperscript{hi} monocytes into the grafts harvested from the ApoE\textsuperscript{−/−} HFD mice compared to wt controls (P < 0.05), whereas there was no significant difference regarding Ly-6C\textsuperscript{lo} monocyte infiltration between the two groups (Fig. 4G).

3.6. Depletion of GR1\textsuperscript{+} inflammatory monocytes and neutrophils decreases TA and intra-graft macrophage accumulation

In order to determine whether the inflammatory monocytes play a pathogenic role in disease progression we treated a group of
ApoE<sup>−/−</sup> HFD mice receiving CBA.Ca arterial grafts with depleting rat anti-mouse anti-GR1 antibodies (clone RB6-8C5; 200 µg/injection) administered i.p. every second day starting at one day before transplantation. The RB6-8C5 antibody binds both Ly-6C on monocytes as well as Ly-6G on neutrophils. Our preliminary experiments showed that the antibody depletes neutrophils and the Ly-6Chi (GR1<sup>hi</sup>) monocyte population, confirming previously published data by Daley et al. [20] (Supplemental Fig. 5). The anti-GR1 antibody treatment significantly decreased intimal expansion and the macrophage content of the lesions by approximately 35% compared with a rat IgG control group (Fig. 5).

4. Discussion

By using a mouse model of arterial transplantation we demonstrate for the first time that the inflammatory Ly-6<sup>Ch</sup> monocytes are involved in the pathogenesis of TA and that hyperlipidemia potently accelerates the recruitment of this distinct cellular population into the grafts. Antibody-mediated depletion of Ly-6<sup>Ch</sup> monocytes and neutrophils decreases macrophage accumulation and lesion development, suggesting an active involvement of these cells in the pathogenesis of the disease. The macrophage-derived foam cells are a major component of the neointima in hyperlipidemic hosts. We found significant correlations between plasma cholesterol, macrophage accumulation and lesion size, suggesting that the increased Ly-6<sup>Ch</sup> monocyte recruitment may act as a link between hypercholesterolemia and the accelerated lesion development. Interestingly, this mechanism seems to be independent of T cell-mediated alloimmunity, as the density of T cells infiltrating the graft remained unchanged in the hyperlipidemic versus the normolipidemic hosts and T cell depletion did not influence macrophage accumulation.

The accelerated TA development in cardiac and vessel allografts in hyperlipidemic animals was previously shown to be associated with increased local expression of VCAM-1 and ICAM-1, enhanced neovascularization and higher levels of TNFα in SMCs [13–15]. Although these studies acknowledged the presence of infiltrating lipids and foam cells, they suggested that the accelerated disease progression is mediated by increased SMC accumulation into the neointima [14,15]. Our results do not contradict this hypothesis, as we have also found a thicker neointimal SMC layer in the arterial grafts from the ApoE<sup>−/−</sup> HFD group compared to wt controls. However, the strong direct correlation between cholesterol levels, macrophage infiltration and lesion size suggests that monocytes/macrophages are a major contributor to the enhanced lesion development in the hyperlipidemic environment. In grafts harvested from the ApoE<sup>−/−</sup> HFD recipients, the CD68<sup>+</sup> immunostained area accounts for up to 30% of the total size of the lesion but, as the detection antibody only binds to cellular membrane, the total area occupied by lipid-loaded foam cells is in fact much larger. In

---

**Fig. 3.** T cell depletion does not influence macrophage accumulation into the neointima. Quantification of CD4 T cell infiltration into allografts harvested from the normolipidemic wt (n = 5) and hyperlipidemic ApoE<sup>−/−</sup> HFD (n = 7) mice expressed as total number of infiltrating cells per section (A) and as number of cells reported to the area of the lesion (B). (C, D) Lesion development and macrophage recruitment in allografts harvested from ApoE<sup>−/−</sup> HFD recipients treated with depleting anti-CD4 and anti-CD8 antibodies (n = 6) compared to a rat IgG control group (n = 6). * P < 0.05, *** P < 0.001. HFD, high fat diet.
Fig. 4. Hyperlipidemia accelerates the recruitment of inflammatory Ly-6C\textsuperscript{hi} monocytes into the arterial grafts. The fluorescent photomicrographs in (A) and (B) show the presence of green fluorescent microspheres in arterial allografts harvested from ApoE\textsuperscript{-/-} HFD mice in which the Ly-6C\textsuperscript{lo} (GR1\textsuperscript{lo}) (A) and the Ly-6C\textsuperscript{hi} (GR1\textsuperscript{hi}) (B) monocytes were labelled. The latex microspheres were injected 10 days after transplantation and the grafts were harvested 4 days later. Blue is DAPI nuclear stain, the elastic laminae in the media are green autofluorescent and the white arrows indicate the location of the fluorescent microspheres. (C, D) Red immunofluorescent staining of CD11b\textsuperscript{+} (C) and GR1\textsuperscript{+} (D) cells in graft sections from the ApoE\textsuperscript{-/-} HFD Ly-6C\textsuperscript{hi} group showing infiltration of both microsphere\textsuperscript{-} and microsphere\textsuperscript{+} CD11b\textsuperscript{-} and GR1\textsuperscript{-} cells into the neointima, with the majority of the latex microspheres located inside the cells. (D, F) Four times enlargement of the marked areas in (C) and (E) demonstrating the intracellular location of the microspheres. (G) Fluorescent microsphere infiltration into the neointima of allogeneic aortic grafts harvested from 2 groups of wt recipients fed a regular mouse diet and 2 groups of ApoE\textsuperscript{-/-} HFD recipients in which the Ly-6C\textsuperscript{lo} and the Ly-6C\textsuperscript{hi} monocytes were differentially labelled (n = 6 mice per group). Microsphere density was quantified as percentage microsphere\textsuperscript{-} area per total lesion area. * P < 0.05, ** P < 0.01. HFD, high fat diet.
contrast, macrophages occupy only 6% of the neointima in the lesions developed in normolipidemic hosts.

Similar to native atherosclerosis, lipid infiltration and oxLDL accumulation inside the vascular wall seems to trigger the recruitment of monocytes in an attempt to clear the infiltrating lipids from the tissue [21]. We found that the presence of oxLDL is exclusively confined to the inner layers of the media. This is a distinctive feature of TA, as in native atherosclerosis the oxLDL-associated epitopes can be detected throughout the atheroma [17]. OxLDL is pro-inflammatory and immunogenic and has been shown to trigger accumulation and activation of macrophages, T cells and SMC [21–23]. It appears that the accelerated foam cell accumulation and SMC proliferation occur in parallel through local mechanisms triggered by the increased lipid infiltration and oxidation.

It has previously been suggested that macrophages might be involved in the pathogenesis of TA, as phagocyte depletion inhibited development of cardiac allograft vasculopathy in a mouse model of heart transplantation [24]. We demonstrate that the Ly-6C<sup>hi</sup> monocytes are preferentially recruited into the neointima compared to their Ly-6C<sup>lo</sup> counterparts both in the normolipidemic and in the hyperlipidemic hosts and that hyperlipidemia specifically accelerates this process. Our data extend previous studies by other groups showing that Ly-6C<sup>hi</sup> monocytes preferentially develop into plaque macrophages and dendritic cells in atherosclerotic lesions [18,25] and are the main monocyte population associated with rejection of murine heart allografts [26]. Antibody-mediated depletion of Ly-6C<sup>hi</sup> monocytes and neutrophils significantly decreased macrophage accumulation and delayed disease progression. It is difficult to speculate whether these effects are mainly due to Ly-6C<sup>monocyte</sup> depletion or whether neutrophils also play a role. The involvement of neutrophils in the pathogenesis of TA is currently unknown and certainly warrants further investigation. In the case of native atherosclerosis, recruitment of inflammatory Ly-6C<sup>hi</sup> monocytes into the atherosclerotic plaques requires particular chemokine—chemokine receptor interactions, involving CXCR1 in addition to CCR2 and CCR5 [18]. It remains to be determined whether similar pathways are involved in the recruitment of inflammatory monocytes into the arterial grafts. Identifying the key chemokines and chemokine receptors involved in this process might provide treatment targets for specifically restricting the involvement of Ly-6C<sup>hi</sup> monocytes in the development of allograft vasculopathy.

T cells play a major role in the pathogenesis of TA. Interestingly, the density of CD4<sup>+</sup> T cells inside the lesions was similar in grafts harvested from ApoE<sup>−/−</sup> HFD mice and wt controls. Treatment of ApoE<sup>−/−</sup>-HFD recipients with depleting anti T cell antibodies led to significantly smaller lesions compared to controls, but did not influence the rate of macrophage accumulation. These observations suggest that the effect of hyperlipidemia on lesion formation is not T cell mediated and that the accumulating macrophages do not accelerate disease by triggering an increased recruitment of T cells into the graft. Our results are in line with previous findings demonstrating that inhibition of macrophage phagocytosis and antigen-presentation with gadolinium chloride did not delay the development of coronary allograft vasculopathy in mice [24].

The recruitment of Ly-6C<sup>hi</sup> monocytes into the neointima in the ApoE<sup>−/−</sup> mice on a HFD occurs at a much faster pace than that observed in native atherosclerosis [18], confirming that the pathogenesis of TA employs an accelerated inflammatory and hyperplastic process compared to native atheromas [3]. These findings correlate with data from previous experimental and clinical studies that have demonstrated a much higher accumulation of lipids over a shorter time period in the coronary arteries of transplanted hearts compared to native atherosclerosis [12,13]. A potential drawback of our model is that plasma lipid levels are much higher in the ApoE<sup>−/−</sup> mice fed a HFD compared to human subjects, and therefore we cannot rule out that this might have exacerbated effects on lesion progression. Additionally, our data and studies by other groups demonstrate a marked escalation in the total numbers of circulating monocytes in the ApoE<sup>−/−</sup> mice fed a HFD, mainly due to an increase in the Ly-6C<sup>hi</sup> population [18,25–27]. Consecutively, it is possible that the increased availability of circulating inflammatory monocytes might have contributed to the highly exacerbated disease progression in the ApoE<sup>−/−</sup>-HFD group. However, the correlation between plasma cholesterol levels, macrophage accumulation and the size of the neointima was also valid in the ApoE<sup>−/−</sup>-mice fed a regular mouse diet, which have much lower lipid levels and similar total and Ly-6C<sup>hi</sup> monocyte counts as the wt controls [25]. These observations suggest that the local environment of the neointima, characterised by intense lipid infiltration and oxidative modifications, plays an important role in the preferential recruitment of the inflammatory monocytes into the arterial allografts. The histological similarity between the grafts harvested from the ApoE<sup>−/−</sup>-recipients and the appearance of coronary arteries in necropsy specimens from transplanted human hearts [12] indicates that this is an accelerated model which might accurately reflect the events that occur at a slower rate in the clinical setting. We propose the ApoE<sup>−/−</sup>-mice as a more appropriate recipient strain for studies of transplant-associated vascular pathology than wt mice, as the wt models do not reflect the hyperlipidemic conditions that often occur in transplant patients.

Fig. 5. Depleting anti-GR1 antibody treatment decreases TA development and macrophage accumulation into the neointima (A) Lesion development in CBA.Ca grafts harvested from ApoE<sup>−/−</sup> HFD recipients treated with depleting anti-GR1 antibodies (n = 7) or rat IgG (n = 6). (B) Macrophage content in the neointima of grafts harvested from the anti-GR1 and the control IgG groups. * P < 0.05.
5. Conclusions

To our knowledge, this is the first report describing the important role played by the inflammatory Ly-6C\textsuperscript{hi} monocytes in the pathogenesis of TA. Our data provide a possible mechanistic explanation for the previously reported correlation between hyperlipidemia, severe coronary vasculopathy and increased prevalence of adverse cardiac events in heart transplant recipients [8–11]. The accumulation of macrophage-derived foam cells in the arterial allografts occurs independently of T cells and correlates well with plasma cholesterol levels and the size of the lesions. From a clinical perspective, our findings support current guidelines recommending early post-transplant lipid-lowering therapy. Statins have been shown to prevent hypercholesterolemia-associated monocytosis in mice [25] and to delay coronary allograft vasculopathy in mice [26] and to delay coronary allograft vasculopathy in humans, significantly improving survival rates of cardiac transplant recipients [28]. While the current immunosuppressive therapies are mainly directed against lymphocyte activation and proliferation, other cellular populations have largely been overlooked so far. The ability of the immunosuppressive drug rapamycin to inhibit monocyte infiltration into the arterial wall [29] might partly explain its demonstrated superior efficiency compared to other immunosuppressants for the prevention of coronary allograft vasculopathy [30]. Our study identifies the Ly-6C\textsuperscript{hi} inflammatory monocytes as new potential therapeutic targets for further improvement of long-term survival in heart transplant recipients.

Sources of financial support

The study was supported by grants from the Garfield Weston Trust, The Wellcome Trust and British Heart Foundation. Dr. Schiopu was supported by the Swedish Heart and Lung Foundation and the Swedish Research Council. Dr. Nadig was an International Society for Heart and Lung Transplantation Research Fellow. The funding source(s) were not directly involved in study design, collection, analysis and interpretation of data, writing of the report or in the decision to submit the article for publication.

Conflicts of interest and relationships with the industry

None.

Acknowledgements

The authors would like to thank Prof. Keith Channon and Dr. Nicholas Alp for the gift of ApoE\textsuperscript{−/−} mice and the staff at the BMS–JR for the expert care of the mice used in this study. The authors would like to thank Dr Nicholas Jones and Dr. Andrew Bushell for helpful discussions during the course of the project.

Appendix A. Supplementary material

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.atherosclerosis.2012.05.010.

References

[1] Hunt SA, Haddad F. The changing face of heart transplantation. J Am Coll Cardiol 2008;52:587–98.
[2] Schmauss D, Weis M. Cardiac allograft vasculopathy: recent developments. Circulation 2008;117:2131–41.
[3] Rahmani M, Cruz RP, Granville DJ, McManus BM. Allograft vasculopathy versus atherosclerosis. Circ Res 2006;99:801–15.
[4] Hillebrands JL, Rozing J. Chronic transplant dysfunction and transplant arteriosclerosis: new insights into underlying mechanisms. Expert Rev Mol Med 2003;5:1–23.
[5] Taylor DO, Edwards LB, Boucek MM, et al. Registry of the international society for heart and lung transplantation: twenty-fourth official adult heart transplant report–2007. J Heart Lung Transplant 2007;26:769–81.
[6] Valantine H. Cardiac allograft vasculopathy after heart transplantation: risk factors and management. J Heart Lung Transplant 2004;23:5187–93.
[7] Tuzcu EM, Kapadia SR, Sacher R, et al. Intravascular ultrasound evidence of angiographically silent progression in coronary atherosclerosis predicts long-term morbidity and mortality after cardiac transplantation. J Am Coll Cardiol 2004;45:1538–42.
[8] Winters GL, Kendall TJ, Radio SJ, et al. Posttransplant obesity and hyperlipidemia: major predictors of severity of coronary artery arteriopathy in failed heart allografts. J Heart Transplant 1990;9:364–71.
[9] Eich D, Thompson JA, Ko Dj, et al. Hypercholesterolemia in long-term survivors of heart transplantation: an early marker of accelerated coronary artery disease. J Heart Lung Transplant 1991;10:45–9.
[10] Kobashigawa JA, Kasikie BL. Hyperlipidemia in solid organ transplantation. Transplantation 1997;63:331–8.
[11] Kobashigawa JA, Starling RC, Mehra MR, et al. Multicenter retrospective analysis of cardiovascular risk factors affecting long-term outcome of de novo cardiac transplant recipients. J Heart Lung Transplant 2006;25:1063–9.
[12] McManus BM, Horley KJ, Wilson JE, et al. Prominence of coronary arterial wall lipids in human heart allografts. Implications for pathogenesis of allograft arteriopathy. Am J Pathol 1995;147:293–308.
[13] Russell PS, Chase CM, Colvin RB. Accelerated atheromatous lesions in mouse hearts transplanted to apolipoprotein-E-deficient recipients. Am J Pathol 1996;149:91–9.
[14] Shi C, Lee WS, Russell ME, et al. Hypercholesterolemia exacerbates transplant arteriosclerosis via increased neointimal smooth muscle cell accumulation; studies in apolipoprotein E knockout mice. Circulation 1997;96:2722–8.
[15] Tanaka H, Sukhova GK, Libby P. Interaction of the allogeneic state and hypercholesterolemia in arterial lesion formation in experimental cardiac allografts. Arterioscler Thromb 1994;14:734–45.
[16] Ensminger SM, Billing JS, Morris PJ, Wood KJ. Development of a combined cardiac and aortic transplant model to investigate the development of transplant arteriosclerosis in the mouse. J Heart Transplant 2000;19:1039–46.
[17] Schiopu A, Bengtsson J, Soderberg I, et al. Recombinant human antibodies against aldhyde-modified apolipoprotein B-100 peptide sequences inhibit atherosclerosis. Circulation 2004;110:2047–52.
[18] Tacke F, Alvarez D, Kaplan TJ, et al. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest 2007;118:185–94.
[19] Geissmann F, Jung S, Littman DR. Monocytes consist of two principal subsets with distinct migratory properties. Immunity 2003;19:71–82.
[20] Daley JM, Thomay AA, Connolly MD, Richer JS, Albina JE. Use of Ly6G−/Ly6C− myeloid cells in organ rejection in mice. J Clin Investig 2010;120:2627–34.
[21] Murphy AJ, Akhtari M, Tolani S, et al. ApoE regulates hematopoietic stem cell proliferation, monocytosis, and monocye accumulation in atherosclerotic lesions in mice. J Clin Investig 2011;121:4138–49.
[22] Wemen K, Meiser B, Thiery J, et al. Simvastatin initiated early after heart transplantation: 8-year prospective experience. Circulation 2003;107:93–7.
[23] Pakala R, Stabile E, Jung GJ, Quiocho L, Waksman R. Rapamycin attenuates atherosclerotic plaque progression in apolipoprotein E knockout mice: inhibitory effect on monocyte chemotaxis. J Cardiovasc Pharmacol 2005;46:481–6.
[24] Schiopu A, Richardson M, Ryuqyop P, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation 2004;110:2694–700.